Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1
Authors:
- David A. CooperDCDavid A. Cooper
- Sharon WalmsleySWSharon Walmsley
- Adriano LazzarinALAdriano Lazzarin
Open Access
- 13 March 2014
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 28 (5) , 717-725
Abstract
Maraviroc, a chemokine co-receptor type 5 (CCR5) antagonist, has demonstrated comparable efficacy and safety to efavirenz, each in combination with zidovudine/lamivudine, over 96 weeks in the Maraviroc vs. Efavirenz Regimens as Initial Therapy (MERIT) study. Here we report 5-year findings. A randomized, double-blind, multicenter phase IIb/III study with an open-label extension phase. Treatment-naive patients with CCR5-tropic HIV-1 infection (Trofile) received maraviroc 300 mg twice daily or efavirenz 600 mg once daily, and zidovudine/lamivudine 300 mg/150 mg twice daily. After the last patient's week 96 visit, the study was unblinded and patients could enter a nominal 3-year open-label phase. Endpoints at the 5-year nominal visit (week 240) included proportion of patients (CCR5 tropism re-confirmed by enhanced sensitivity Trofile) with viral load (plasma HIV-1 RNA) below 50 and 400 copies/ml, and change from baseline in CD4(+) cell count, as well as safety. The proportion of patients maintaining viral load below 50 copies/ml was similar between treatment arms throughout the study and at week 240 (maraviroc 50.8% vs. efavirenz 45.9%). Maraviroc-treated patients had a greater increase from baseline in mean CD4(+) cell count than efavirenz-treated patients at week 240 (293 vs. 271 cells/μl, respectively). Fewer patients on maraviroc vs. efavirenz experienced treatment-related adverse events (68.9 vs. 81.7%) and discontinued as a result of any adverse event (10.6 vs. 21.3%). Maraviroc maintained similar long-term antiviral efficacy to efavirenz over 5 years in treatment-naive patients with CCR5-tropic HIV-1. Maraviroc was generally well tolerated with no unexpected safety findings or evidence of long-term safety concerns.Keywords
This publication has 27 references indexed in Scilit:
- Long-Term Efficacy, Safety, and Tolerability of Rilpivirine (RPV, TMC278) in HIV Type 1-Infected Antiretroviral-Naive Patients: Week 192 Results from a Phase IIb Randomized TrialAIDS Research and Human Retroviruses, 2012
- Reanalysis of Coreceptor Tropism in HIV-1-Infected Adults Using a Phenotypic Assay with Enhanced SensitivityClinical Infectious Diseases, 2011
- Two-Year Safety and Virologic Efficacy of Maraviroc in Treatment-Experienced Patients With CCR5-Tropic HIV-1 Infection: 96-Week Combined Analysis of MOTIVATE 1 and 2JAIDS Journal of Acquired Immune Deficiency Syndromes, 2010
- The Relationship of CCR5 Antagonists to CD4+ T-Cell Gain: A Meta-Regression of Recent Clinical Trials in Treatment-Experienced HIV-Infected PatientsHIV Research & Clinical Practice, 2010
- Hepatic safety and tolerability in the maraviroc clinical development programAIDS, 2010
- Lymphoma Diagnosis and Plasma Epstein‐Barr Virus Load during Vicriviroc Therapy: Results of the AIDS Clinical Trials Group A5211Clinical Infectious Diseases, 2009
- Maraviroc for Previously Treated Patients with R5 HIV-1 InfectionNew England Journal of Medicine, 2008
- Case of Yellow Fever Vaccine–Associated Viscerotropic Disease with Prolonged Viremia, Robust Adaptive Immune Responses, and Polymorphisms in CCR5 and RANTES GenesThe Journal of Infectious Diseases, 2008
- Hepatotoxicity Observed in Clinical Trials of Aplaviroc (GW873140)Antimicrobial Agents and Chemotherapy, 2008
- Evidence for negative association of the chemokine receptor CCR5 d32 polymorphism with rheumatoid arthritisAnnals of the Rheumatic Diseases, 2005